Revolution Medicines` Daraxonrasib Gets FDA Orphan Status
27 Oct 2025 //
GLOBENEWSWIRE
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236)
16 Oct 2025 //
GLOBENEWSWIRE
Revolution Begin RASolute 303 Trial for Pancreatic Adenocarcinoma
10 Sep 2025 //
GLOBENEWSWIRE
Revolution Wins FDA Breakthrough Tag for Daraxonrasib
23 Jun 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support